Tolerogenic insulin peptide therapy precipitates type 1 diabetes

Daniel et al. (https://doi.org/10.1084/jem.20110574) have previously published in JEM a study on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Our study now challenges these results and shows that osmotic pump delivery of the modified ins...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergman, Marie-Louise, Lopes-Carvalho, Thiago, Martins, Ana-Catarina, Grieco, Fabio A., Eizirik, Décio L., Demengeot, Jocelyne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2017
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502418/
https://www.ncbi.nlm.nih.gov/pubmed/28536239
http://dx.doi.org/10.1084/jem.20160471
Descripción
Sumario:Daniel et al. (https://doi.org/10.1084/jem.20110574) have previously published in JEM a study on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Our study now challenges these results and shows that osmotic pump delivery of the modified insulin peptide R22E did not prevent hyperglycemia, accelerated disease onset, increased its incidence, and worsened insulitis.

Ejemplares similares